Skip to main content
Reimbursement strategy

Market Access Strategy for Medical Devices in Europe

Strategic recommendations on the topic of market access pathways for medical devices and IVD tests

Learn more

White Paper: Challenges of HTA and Reimbursement Submissions for Medical Devices

Get insights from MTRC White Papers to explore the complexities of reimbursement and HTA submissions for medical devices in Europe and discover practical solutions to overcome these challenges

Request free of charge
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Consultation on the update of NICE-wide Topic Prioritisation manual in England

On April 22, 2026, NICE published an updated NICE-wide Topic Prioritisation manual (PMG46) for consultation. The manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritized, and routed at NICE, and the decision-making framework used by the NICE prioritization board.

The key changes include the following:

  • What NICE will consider as priority areas for NICE guidance and portfolio maintenance, and be clear about which topics are outside of NICE’s remit;
  • The introduction of flexibility in routing decisions to support the Whole Life Cycle Approach to guidance. For example, updates can be routed to any guidance-producing programs and combinations of more than one type of guidance;
  • The routing of HealthTech topics to technology appraisal (as part of the new National HealthTech Access Program, NHAP) is now clearly described. If the HealthTech topic was prioritized for routine-use HealthTech guidance, the NICE prioritization board can also make further proposals to the Secretary of State to develop NHAP guidance using NICE technology appraisal methods and processes;
  • Criteria are set, which will be considered for the re-evaluation of early-use HealthTech guidance to routine-use HealthTech guidance.

The deadline for comment submission is May 19, 2026.

See more details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.